IP Library Granted Patent US 7,375,181
Granted Patent B2
US 7,375,181 · App. 11/301,740 · Granted May 20, 2008

Process for purifying glycopeptide phosphonate derivatives

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,375,181
App. No.
11/301,740
Granted
May 20, 2008
Kind
B2
Abstract

Disclosed are methods of purifying glycopeptides that are substituted with one or more substituents each comprising one or more phosphono groups that are useful as antibacterial agents. The methods include contacting a solution of the glycopeptide derivatives with a polystyrene-containing resin, eluting the resin with an aqueous solution, and isolating the purified glycopeptide derivative.

Claims (23)

1. A method of purifying a compound of formula I:

wherein:

R 19 is hydrogen;

R 20 is —CH 2 CH 2 —NH—(CH 2 ) 9 CH 3 ;

R 3 is —OH;

R 5 is —CH 2 —NH—CH 2 —P(O)(OH) 2 ;

or a pharmaceutically acceptable salt or stereoisomer, thereof;

the method comprising the steps of:

(a) contacting a polystyrene divinyl benzene resin with a first acidified aqueous solution comprising the compound;

(b) eluting the contacted resin with a second acidified aqueous solution comprising a polar organic solvent selected from methanol, ethanol, isopropyl alcohol, acetonitrile, acetone, n-propyl alcohol, n-butyl alcohol, isobutyl alcohol, methyl ethyl ketone, and tetrahydrofuran to form an eluate containing the compound; and

(c) isolating the compound from the eluate.

2. The method of claim 1 , wherein the second acidified aqueous solution contains acetic acid.

3. The method of claim 1 , wherein the second acidified aqueous solution contains hydrochloric acid.

4. The method of claim 1 , wherein the polystyrene divinyl benzene resin has a ROTC size of from about 50 Å to about 1000 Å.

5. The method of claim 1 , wherein the compound is a pharmaceutically acceptable salt.

6. The method of claim 1 , wherein the compound is a hydrochloride salt.

7. The method of claim 1 , wherein the compound is an acetate salt.

8. The method of claim 1 , wherein the polystyrene divinyl benzene resin has a particle bead size in the range of between about 20 μm to about 800 μm.

9. The method of claim 1 , wherein the first acidified aqueous solution contains acetic acid.

10. The method of claim 1 , wherein the first acidified aqueous solution contains hydrochloric acid.

11. The method of claim 1 , wherein the polar organic solvent is methanol, ethanol, isopropyl alcohol or acetonitrile.

12. The method of claim 1 , wherein the polar organic solvent is ethanol.

13. The method of claim 1 , wherein the polar organic solvent is acetonitrile.

Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 14, 2018
From: THERAVANCE BIOPHARMA ANTIBIOTICS IP, LLC
To: CUMBERLAND PHARMACEUTICALS INC.
Reel/Frame 047909/0853 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 10, 2014
From: THERAVANCE, INC.
To: THERAVANCE BIOPHARMA ANTIBIOTICS IP, LLC
Reel/Frame 033179/0897 →